BG107330A - Substituted imidazoles as tafia inhibitors - Google Patents

Substituted imidazoles as tafia inhibitors

Info

Publication number: BG107330A
Authority: BG; Bulgaria
Prior art keywords: tafia inhibitors; substituted imidazoles; compounds; tafia; inhibitors
Prior art date: 2000-08-17

Application number

BG107330A

Other languages

Bulgarian (bg)

English (en)

Inventor

Charlotte ALLERTON

Julian Blagg

Mark Bunnage

John Steele

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-17

Filing date

2002-11-28

Publication date

2003-06-30

2000-08-17 Priority claimed from GB0020346A external-priority patent/GB0020346D0/en

2000-11-09 Priority claimed from GB0027409A external-priority patent/GB0027409D0/en

2000-12-04 Priority claimed from GB0029556A external-priority patent/GB0029556D0/en

2002-11-28 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2003-06-30 Publication of BG107330A publication Critical patent/BG107330A/xx

Links

239000003112 inhibitor Substances 0.000 title abstract 2
150000002460 imidazoles Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
101800004538 Bradykinin Proteins 0.000 abstract 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
102100035792 Kininogen-1 Human genes 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000002500 effect on skin Effects 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000003176 fibrotic effect Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000037390 scarring Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

BG107330A 2000-08-17 2002-11-28 Substituted imidazoles as tafia inhibitors BG107330A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0020346A GB0020346D0 (en)	2000-08-17	2000-08-17	Pharmaceuticals
GB0027409A GB0027409D0 (en)	2000-11-09	2000-11-09	Pharmaceuticals
GB0029556A GB0029556D0 (en)	2000-12-04	2000-12-04	Pharmaceuticals
PCT/IB2001/001425 WO2002014285A1 (en)	2000-08-17	2001-08-08	Substituted imidazoles as tafia inhibitors

Publications (1)

Publication Number	Publication Date
BG107330A true BG107330A (en)	2003-06-30

Family

ID=27255849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107330A BG107330A (en)	2000-08-17	2002-11-28	Substituted imidazoles as tafia inhibitors

Country Status (38)

Country	Link
EP (1)	EP1311488B1 (is)
JP (2)	JP4119746B2 (is)
KR (1)	KR20030022412A (is)
CN (1)	CN1443173A (is)
AP (1)	AP1375A (is)
AR (1)	AR035580A1 (is)
AT (1)	ATE447557T1 (is)
AU (1)	AU2001276605A1 (is)
BG (1)	BG107330A (is)
BR (1)	BR0113289A (is)
CA (1)	CA2419633C (is)
CY (1)	CY1109693T1 (is)
CZ (1)	CZ2003388A3 (is)
DE (1)	DE60140368D1 (is)
DK (1)	DK1311488T3 (is)
DO (1)	DOP2001000233A (is)
EA (1)	EA005532B1 (is)
EE (1)	EE200300070A (is)
ES (1)	ES2334101T3 (is)
HR (1)	HRP20030103A2 (is)
HU (1)	HUP0303763A3 (is)
IL (1)	IL153225A0 (is)
IS (1)	IS6638A (is)
MA (1)	MA26940A1 (is)
MX (1)	MXPA03001425A (is)
NO (1)	NO20030706L (is)
NZ (1)	NZ522823A (is)
OA (1)	OA12362A (is)
PA (1)	PA8525401A1 (is)
PE (1)	PE20020352A1 (is)
PL (1)	PL361054A1 (is)
PT (1)	PT1311488E (is)
SI (1)	SI1311488T1 (is)
SK (1)	SK1732003A3 (is)
SV (1)	SV2002000602A (is)
TN (1)	TNSN01126A1 (is)
UY (1)	UY26889A1 (is)
WO (1)	WO2002014285A1 (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103272D0 (sv)	2001-09-28	2001-09-28	Astrazeneca Ab	Chemical compounds
US6713496B2 (en)	2002-01-22	2004-03-30	Pfizer Inc	3-(imidazolyl)-2-alkoxypropanoic acids
BR0307033A (pt) *	2002-01-22	2004-12-07	Pfizer	ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
HRP20040659A2 (en) *	2002-01-22	2004-10-31	Pfizer	3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
EP1618380B1 (en) *	2003-04-29	2009-12-30	Universität Zürich	N epsilon AND/OR N alpha DERIVATIZED, METAL AND ORGANIC PROTECTED L-HISTIDINE FOR COUPLING TO BIOMOLECULES FOR HIGHLY EFFICIENT LABELING WITH (M(OH2)3(CO)3)+ BY FAC COORDINATION
SE0302853D0 (sv) *	2003-10-29	2003-10-29	Astrazeneca Ab	Chemical compounds
WO2005049027A2 (en) *	2003-11-03	2005-06-02	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
WO2005051384A1 (en) *	2003-11-25	2005-06-09	Pfizer Limited	Stabilised pharmaceutical compositions
US20060234986A1 (en) *	2005-04-18	2006-10-19	Schering Aktiengesellschaft	Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI
DE102005049385A1 (de)	2005-10-15	2007-04-19	Sanofi-Aventis Deutschland Gmbh	Imidazolderivate als Inhibitoren von TAFIa
PT2104497E (pt) *	2006-12-06	2015-06-09	Sanofi Sa	Derivados de ureia e sulfamida enquanto inibidores de tafia
EP2262783A2 (en) *	2008-02-21	2010-12-22	Sanofi-Aventis	Covalently binding imaging probes
NZ592764A (en) *	2008-10-29	2012-08-31	Taisho Pharmaceutical Co Ltd	Compound having tafia inhibitory activity
FR2947266B1 (fr) *	2009-06-26	2011-06-17	Servier Lab	Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2791505C (en)	2010-03-18	2016-06-07	Daiichi Sankyo Company, Limited	Cycloalkyl-substituted imidazole derivative
CN102884053B (zh) *	2010-03-18	2016-03-02	第一三共株式会社	环丙烷甲酸衍生物
SI2716684T1 (sl) *	2011-05-17	2019-11-29	Pharmasyntez	Spojine za profilakso in postopek za zdravljenje adhezijskega postopka
IN2014DN00144A (is) *	2011-07-22	2015-05-22	Cambrex Karlskoga Ab
WO2013039202A1 (ja) *	2011-09-15	2013-03-21	第一三共株式会社	新規アクリル酸誘導体
JP6461113B2 (ja)	2013-06-10	2019-01-30	サノフイＳａｎｏｆｉ	ＴＡＦＩａの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用
MX392524B (es)	2015-10-07	2025-03-24	Salk Inst Biological Studies	Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
FR3046793B1 (fr) *	2016-01-14	2018-01-05	Les Laboratoires Servier	Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20190117624A1 (en) *	2016-03-29	2019-04-25	Daiichi Sankyo Company, Limited	Therapeutic agent for inflammatory bowel diseases
BR112018069930B1 (pt)	2016-04-13	2024-02-20	Mitobridge, Inc	Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica
CN113943255B (zh) *	2020-07-17	2024-08-06	深圳信立泰药业股份有限公司	一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6163661A (ja) *	1984-09-05	1986-04-01	Microbial Chem Res Found	ヒスタジン関連化合物
US5993815A (en) *	1996-11-08	1999-11-30	University Of Vermont	Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) *	1999-05-03	1999-05-03	Astra Ab	New compounds

2001
- 2001-08-08 SI SI200130950T patent/SI1311488T1/sl unknown
- 2001-08-08 JP JP2002519428A patent/JP4119746B2/ja not_active Expired - Fee Related
- 2001-08-08 HR HR20030103A patent/HRP20030103A2/hr not_active Application Discontinuation
- 2001-08-08 PL PL36105401A patent/PL361054A1/xx not_active Application Discontinuation
- 2001-08-08 NZ NZ522823A patent/NZ522823A/en unknown
- 2001-08-08 HU HU0303763A patent/HUP0303763A3/hu unknown
- 2001-08-08 EP EP01954264A patent/EP1311488B1/en not_active Expired - Lifetime
- 2001-08-08 BR BR0113289-0A patent/BR0113289A/pt not_active Application Discontinuation
- 2001-08-08 CA CA2419633A patent/CA2419633C/en not_active Expired - Fee Related
- 2001-08-08 AU AU2001276605A patent/AU2001276605A1/en not_active Abandoned
- 2001-08-08 DK DK01954264T patent/DK1311488T3/da active
- 2001-08-08 IL IL15322501A patent/IL153225A0/xx unknown
- 2001-08-08 AT AT01954264T patent/ATE447557T1/de active
- 2001-08-08 ES ES01954264T patent/ES2334101T3/es not_active Expired - Lifetime
- 2001-08-08 WO PCT/IB2001/001425 patent/WO2002014285A1/en not_active Ceased
- 2001-08-08 KR KR10-2003-7002279A patent/KR20030022412A/ko not_active Ceased
- 2001-08-08 SK SK173-2003A patent/SK1732003A3/sk unknown
- 2001-08-08 PT PT01954264T patent/PT1311488E/pt unknown
- 2001-08-08 EA EA200201239A patent/EA005532B1/ru not_active IP Right Cessation
- 2001-08-08 EE EEP200300070A patent/EE200300070A/xx unknown
- 2001-08-08 OA OA1200300039A patent/OA12362A/fr unknown
- 2001-08-08 CZ CZ2003388A patent/CZ2003388A3/cs unknown
- 2001-08-08 DE DE60140368T patent/DE60140368D1/de not_active Expired - Lifetime
- 2001-08-08 CN CN01813131A patent/CN1443173A/zh active Pending
- 2001-08-08 MX MXPA03001425A patent/MXPA03001425A/es active IP Right Grant
- 2001-08-14 PA PA20018525401A patent/PA8525401A1/es unknown
- 2001-08-15 AR ARP010103900A patent/AR035580A1/es unknown
- 2001-08-15 UY UY26889A patent/UY26889A1/es not_active Application Discontinuation
- 2001-08-15 PE PE2001000815A patent/PE20020352A1/es not_active Application Discontinuation
- 2001-08-16 TN TNTNSN01126A patent/TNSN01126A1/fr unknown
- 2001-08-16 SV SV2001000602A patent/SV2002000602A/es unknown
- 2001-08-16 AP APAP/P/2001/002250A patent/AP1375A/en active
- 2001-11-14 DO DO2001000233A patent/DOP2001000233A/es unknown
2002
- 2002-11-28 BG BG107330A patent/BG107330A/xx unknown
- 2002-11-28 IS IS6638A patent/IS6638A/is unknown
2003
- 2003-02-04 MA MA27025A patent/MA26940A1/fr unknown
- 2003-02-14 NO NO20030706A patent/NO20030706L/no not_active Application Discontinuation
2008
- 2008-02-27 JP JP2008045382A patent/JP4778531B2/ja not_active Expired - Fee Related
2009
- 2009-12-30 CY CY20091101349T patent/CY1109693T1/el unknown

Also Published As

Publication number	Publication date
BR0113289A (pt)	2003-06-17
UY26889A1 (es)	2002-03-22
ES2334101T3 (es)	2010-03-05
JP4778531B2 (ja)	2011-09-21
KR20030022412A (ko)	2003-03-15
EP1311488A1 (en)	2003-05-21
ATE447557T1 (de)	2009-11-15
AU2001276605A1 (en)	2002-02-25
DOP2001000233A (es)	2002-05-15
JP4119746B2 (ja)	2008-07-16
JP2004506044A (ja)	2004-02-26
AP2001002250A0 (en)	2001-09-30
CA2419633C (en)	2011-05-10
PA8525401A1 (es)	2002-04-25
MXPA03001425A (es)	2003-06-06
SV2002000602A (es)	2002-10-24
HRP20030103A2 (en)	2003-04-30
HUP0303763A2 (hu)	2004-04-28
PL361054A1 (en)	2004-09-20
NZ522823A (en)	2004-11-26
MA26940A1 (fr)	2004-12-20
CA2419633A1 (en)	2002-02-21
IL153225A0 (en)	2003-07-06
AR035580A1 (es)	2004-06-16
DK1311488T3 (da)	2010-01-04
PT1311488E (pt)	2009-12-30
OA12362A (en)	2004-04-07
PE20020352A1 (es)	2002-05-11
EA005532B1 (ru)	2005-04-28
WO2002014285A1 (en)	2002-02-21
TNSN01126A1 (fr)	2005-11-10
EA200201239A1 (ru)	2003-08-28
SI1311488T1 (sl)	2010-01-29
CN1443173A (zh)	2003-09-17
NO20030706L (no)	2003-04-15
SK1732003A3 (en)	2004-08-03
JP2008169224A (ja)	2008-07-24
EE200300070A (et)	2005-02-15
HUP0303763A3 (en)	2004-06-28
IS6638A (is)	2002-11-28
NO20030706D0 (no)	2003-02-14
DE60140368D1 (de)	2009-12-17
EP1311488B1 (en)	2009-11-04
CZ2003388A3 (cs)	2004-03-17
CY1109693T1 (el)	2014-08-13
AP1375A (en)	2005-03-03

Publication	Publication Date	Title
CY1109693T1 (el)	2014-08-13	ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΙΜΙΔΑΖΟΛΙΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ TAFIa
BG105800A (en)	2002-03-29	Benzoheterocycles and their use as mek inhibitors
BG106585A (en)	2003-03-31	Kinase inhibitors as therapeutic agents
YU3902A (sh)	2006-01-16	Imidazoimidazoli i triazoli kao anti-inflamatorna sredstva
PL372926A1 (en)	2005-08-08	Piperidine-pyridazones and phthalazones as pde4 inhibitors
EG25017A (en)	2011-05-25	N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.
BG105270A (en)	2001-11-30	Tetrahydropyridoethers
TW200509949A (en)	2005-03-16	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
CY1110385T1 (el)	2015-04-29	Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
EP1171428A4 (en)	2004-09-15	FAB-I INHIBITORS
ATE332302T1 (de)	2006-07-15	Alkylierte imidazopyridinderivate
ATE311389T1 (de)	2005-12-15	Wirkstoffvorläufer von imidazopyridin-derivaten
NZ332096A (en)	2000-01-28	Alpha-hydroxylic acid derivatives their production and use in treating conditions requiring endothelin inhibition
ATE386742T1 (de)	2008-03-15	Imidazonaphthyridine
DE69823493D1 (de)	2004-06-03	Tetrahydropyridoverbindungen
MY128164A (en)	2007-01-31	Compounds
NO20015892L (no)	2001-12-19	Inhibitorer av metallproteinaser
PL377176A1 (pl)	2006-01-23	N-Sulfonylo-4-metylenoamino-3-hydroksy-2-pirydony
DE60011677D1 (en)	2004-07-22	Tryptase-inhibitoren
DK1244614T3 (da)	2004-09-27	Tryptase-inhibitorer
MXPA02008014A (es)	2004-04-05	Composiciones inhibidoras de tumores de 1-nitroacridina.
DE60216920D1 (en)	2007-02-01	Tryptase-inhibitoren
DE60220504D1 (en)	2007-07-19	Tryptasehemmer
DE60120398D1 (de)	2006-07-20	Imidazopyridin-8-one
ITBO20000360A0 (it)	2000-06-16	Apparecchiatura di elettrostimolazione del corpo umano .